Abstract
Chronic kidney disease (CKD) is known to be a risk factor for end stage renal disease (ESRD) and cardiovascular disease. Therefore, the development of new treatments for CKD is important and necessary. However, there is no established therapy for glomerulosclerosis and renal interstitial fibrosis, which are seen in the kidney of ESRD patients. Recent advances in basic research on the mechanism of fibrosis leads to discovery of fibrosis relating genes or factors. Some anti-fibrotic approaches for targeting these factors have been reported. In this review, we introduce several technologies and methodology using drug delivery system for fibrosis in nephrology.
